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Heterozygous de novo mutations in EEF1A2, encoding the tissue-specific translation elongation factor 
eEF1A2, have been shown to cause neurodevelopmental disorders including often severe epilepsy and 
intellectual disability. The mutational profile is unusual; ~50 different missense mutations have been 
identified but no obvious loss of function mutations, though large heterozygous deletions are known to 
be compatible with life. A key question is whether the heterozygous missense mutations operate through 
haploinsufficiency or a gain of function mechanism, an important prerequisite for design of therapeutic 
strategies. In order both to address this question and to provide a novel model for neurodevelopmental 
disorders resulting from mutations in EEF1A2, we created a new mouse model of the D252H mutation. 
This mutation causes the eEF1A2 protein to be expressed at lower levels in brain but higher in muscle 
in the mice. We compared both heterozygous and homozygous D252H and null mutant mice using 
behavioural and motor phenotyping alongside molecular modelling and analysis of binding partners. 
Although the proteomic analysis pointed to a loss of function for the D252H mutant protein, the D252H 
homozygous mice were more severely affected than null homozygotes on the same genetic background.  
Mice that are heterozygous for the missense mutation show no behavioural abnormalities but do have 
sex-specific deficits in body mass and motor function. The phenotyping of our novel mouse lines, 
together with analysis of molecular modelling and interacting proteins, suggest that the D252H mutation 





Developmental and epileptic encephalopathies (DEE) have profound effects on neurodevelopment and 
are frequently associated with intellectual disability and autism (2). DEEs are now regarded as a 
genetically heterogeneous group of disorders, predominantly resulting from dominant de novo 
mutations, leading to stratification into groups of what are, essentially, individually rare diseases. Whilst 
this genetic granularity will ultimately be helpful in terms of precision medicine, the fact remains that 
over a third of patients with any form of epilepsy remain refractory to treatment with anti-epileptic 
drugs (AEDs). It has been argued that the reliance on induced seizure models in animals for testing 
AEDs has limited progress, and that genetic models of epilepsy will be needed for pharmacological 
advances (3). Furthermore, whilst genetic stratification is crucial in terms of treatment strategies, the 
vast majority of individuals with a precise genetic diagnosis are still young. This means that the long-
term effects of mutations have yet to be established, leaving families with very limited prognostic 
information for the effects of mutations in a given gene. 
One cause of early onset epilepsy that has been established in the last decade is the mutation of a gene 
called EEF1A2. There have now been numerous reports of de novo missense mutations in EEF1A2 
associated with neurodevelopmental disorders (4-13). Surprisingly, although there are now ~50 
different missense mutations in EEF1A2 in children with epilepsy, severe intellectual disability and/or 
autism, no clear loss of function mutations (frameshifts, deletions, nonsense) have ever been identified. 
On the other hand, heterozygous deletions spanning EEF1A2 and neighbouring genes have been 
described and are compatible with life (14, 15). This unusual mutational profile suggests that each 
missense mutation may operate through a gain of function or dominant negative mechanism, but the 
facts that there are so many individual mutations, and that they are spread throughout the gene, makes 
the elucidation of underlying mechanisms a challenge.  
The EEF1A2 gene encodes eEF1A2, a translation elongation factor responsible for the GTP-dependent 
delivery of aminoacylated tRNAs to the ribosome. This GTP exchange mechanism is facilitated by the 
eEF1B complex (16). Whilst most translation factors are ubiquitously expressed, consistent with their 
housekeeping function, eEF1A is found as two independently encoded, tissue-specific variants. 
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Initially, eEF1A1 is expressed ubiquitously throughout development but becomes downregulated in 
postnatal neurons and muscle (both skeletal and cardiac), eventually being completely replaced in these 
cell types by eEF1A2 (17, 18). This process is complete at about 21 days after birth in the mouse; data 
from humans is scarce, but analysis of transcriptional profiles in the human prefrontal cortex suggests 
that eEF1A1 reaches its lowest point between 6 months and 2 years, with eEF1A2 peaking in expression 
by 6 months (http://braincloud.jhmi.edu/plots/) (19). Mice homozygous for a spontaneously occurring 
deletion in the Eef1a2 gene (wasted, gene symbol wst) develop muscle wasting and neurodegeneration 
of the motor neurons in the spinal cord with concomitant gliosis, dying by 25-28 days (20). The wasted 
mutation is a 15.8 kb deletion of the promoter and first exon of the Eef1a2 gene and is a complete null 
(20). On the other hand, mice heterozygous for the wasted deletion live a normal lifespan with no signs 
of neurodegeneration even at 21 months (21). Human and mouse eEF1A2 proteins are almost identical, 
with only one amino acid difference.  
We previously used CRISPR/Cas9 gene editing to recreate in mice the most common epilepsy-causing 
missense mutation seen in humans, G70S (22). We were unable to create a breeding colony of G70S 
mice as all founders carrying the mutation were G70S/- compound heterozygotes and died by ~four 
weeks.  The only G70S-carrying animal without a deletion was homozygous for the missense mutation 
and had to be culled at 18 days, earlier than the stage at which complete null mice start to show any 
signs of the disorder. Whilst this result was compatible with the idea that the G70S mutation confers a 
gain of function on the eEF1A2 protein, it was of course impossible to draw robust conclusions from a 
single animal. We also note that many of the founder animals with biallelic deletions of eEF1A2 had 
spontaneous fatal seizures; this phenomenon had not been documented in the original wasted mouse 
line, which was on a mixed genetic background, so the seizure incidence was presumably influenced 
by the genetic background (C57BL/6) of the CRISPR-derived mice.  
We now report the generation of a new mouse line expressing a different missense mutation in eEF1A2, 
D252H. The D252H mutation has been described twice as a cause of neurodevelopmental disorders, 
once in the published literature (6) and once in the Decipher database (https://decipher.sanger.ac.uk/). 
The mutation is predicted by each of a range of computational tools to be damaging (23). Both affected 
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individuals have severe developmental delay, ID and autism but no or mild, well-controlled epilepsy. 
We therefore opted to recreate the D252H mutation in mice on the basis that it had occurred in more 
than one child, was in a favourable position for repair template design, and was unlikely to give rise to 
fatal seizures in young mice. With this approach, we aimed to have surviving heterozygous mice with 
which to generate breeding lines, to model neurodevelopmental disorders resulting from mutations in 
eEF1A2, and to be able to study behavioural and other phenotypic consequences of missense mutations 
in both heterozygotes and homozygotes.  
We further hypothesised, based on the lack of clear loss of function (deletion, frameshift) clinical 
mutations in humans, that the D252H mutation would cause a gain of function. We were able to harness 
the power of CRISPR/Cas9 gene editing in the mouse to create both missense and null mutations in 
eEF1A2 on the same genetic background. This enabled us to make direct comparisons of the resulting 
phenotypes in order to test the hypothesis that the D252H mutation resulted in a gain of function. 
Coupling our results from mice with molecular modelling and our analysis of interacting proteins, we 





The D252H mutation prevents binding to eEF1B 
The position of the pathogenic D252H mutation on the eEF1A2 protein is shown in Figure 1a, where it 
can be seen to overlap with the mapped binding site for the GTP exchange factor eEF1B (1, 6).  To 
evaluate the effect of the mutation on the eEF1A2 interactome we transiently transfected SHSY5Y 
human neuroblastoma cells with V5 tagged cDNA constructs of human wild type eEF1A2 and human 
eEF1A2 containing the D252H mutation respectively, in parallel with a vector only control. After 48 
hours cell pellets were collected, immunoprecipitated with anti-V5 antibody and the resulting peptides 
analysed using label-free quantification mass spectrometry (LFQ-MS). The most significant change in 
binding resulting from the D252H mutation was a ~500 fold decrease in each of eEF1B2, eEF1D, 
eEF1G and VARS (Figure 1b and supplementary table S1). Together, these proteins make up the eEF1B 
complex that is responsible for GTP exchange on eEF1A. This apparent loss of binding is consistent 
with the position of the mutation on the eEF1A2 protein relative to the eEF1B binding (Figure 1a). The 
results of the LFQ-MS were validated by co-immunoprecipitation (Figure 1c) which showed no 
detectable binding of the eEF1B complex to eEF1A2 carrying the D252H missense mutation. In 
contrast, eEF1A2 with a different pathogenic mutation, G70S (which results in epileptic 
encephalopathy), showed similar levels of eEF1B subunit binding to WT eEF1A2. These results 
suggested a possible loss of function of the D252H mutation; in order to test this in a meaningful 
physiological context we set out to recreate the mutation in mice.  
CRISPR-Cas9 gene editing: design and establishment of breeding lines 
We used CRISPR/Cas9 genome editing to change a single base c.G754C (p.D252H) within the mouse 
Eef1a2 gene.  We designed a pair of gRNAs that would target Eef1a2 in the region of the desired 
mutation (Figure 2a), and two separate 200nt single-stranded oligonucleotide (ssODN) repair templates 
that spanned 100 nucleotides either side of the desired mutation site (supplementary figure S2a). The 
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first ssODN was equivalent to the wild-type sequence of Eef1a2 apart from silent mutations at the two 
PAM-sites, designed to prevent further cutting of the genome after integration 
The second ssODN contained both the silent PAM-site mutations and the c.G754C single base change 
which would encode the D252H mutation when incorporated. The purpose of co-injecting a wild-type 
repair template alongside the mutant template was to decrease the risk of generating mice with biallelic 
mutations in Eef1a2, as these would not be likely to survive long enough to establish a breeding colony 
(22).   
The two repair templates, together with the pair of gRNAs and Cas9 nickase RNA, were micro-injected 
into single cell mouse embryos, resulting in the birth of 28 mice (Figure 2b). Two of these founder mice 
carried the desired mutation on one allele and wild-type sequence on the other (Figure 2c), and are thus 
referred to as D252H/+. These D252H/+ founders were used to establish two separate breeding lines 
carrying the D252H mutation. Initial characterisation was performed on homozygous mice from each 
line independently. There were no significant differences between lines in either weight or neuroscore 
measured at P21 (supplementary figure S2b and c) so subsequent analysis was carried out using 
combined data from both lines. 
 
  
Abundance of eEF1A2 is decreased in brain and increased in muscle of mutant mice  
The D252H mutation results in a dose-dependent decrease in brain eEF1A2 protein levels (Figure 2g, 
2h). The level of eEF1A2 in the brains of D252H/+ mice is ~80% of that seen in WT littermates, and 
the abundance in D252H/D252H brain is ~60% of that seen in WT mice, a statistically significant 
difference (p=0.0006 unpaired two tailed t test). There is no significant difference in expression at the 
RNA level across all three genotypes (Figure 2d and S3c) using 1-way ANOVA, suggesting that the 
mutant protein is likely to be less stable in brain than the WT protein. In contrast, the level of eEF1A2 
in the muscle of mutant animals is the same in D252H/+ heterozygotes as in their wild-type littermates, 
but is ~1.6 times higher in D252H/D252H mice (figure 2e, 2f) (p=0.0002 unpaired two-tailed t test).  
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No significant difference in expression levels was seen between male and female mice within any 
genotype (supplementary figure S3a and b).   
D252H/+ mice weigh less than wild-type littermates and show neurological deficits 
Male and female D252H/+ mice initially follow the same weight growth curve as their WT littermates 
(Figure 3a and 3d). From postnatal day 14 - 21, however, they consistently weigh ~10% less than their 
wild-type littermates (Figure 3b and 3e);  male D252H/+ vs +/+, p=0.0001; female D252H/+ vs +/+, p= 
0.0018. This difference was also apparent in adult mice of both sexes at 2 months: male D252H/+ mice 
weigh 5% less than wild type littermates, (p=0.009) and female D252H/+ mice weigh 10% less than 
their wild type littermates (p=0.001). In contrast, the weights of heterozygous null animals are not 
significantly different from their wild type littermates (Figure S8a and b). 
Since the switch from eEF1A1 to eEF1A2 occurs throughout the first 3-4 weeks of postnatal life in 
mice, and homozygosity for null mutations is lethal by 4 weeks, we needed to develop a scoring system 
that would allow us to distinguish the phenotypic consequences of any mutation in young mice. In order 
to quantify the temporal progression of any neurological abnormalities we used an adaptation of the 
phenotype scoring system described by Guyenet et al.(25) in which four tests (degree of hind limb 
clasping, gait, kyphosis and  ability to walk along a ledge), are each given a score between 0 and 3.  
Criteria for each score are given in the supplementary methods 1. The combined neuroscore, obtained 
by adding together the four individual test scores, gives a measure of phenotypic severity. This 
neuroscore is particularly useful for pre-weaning mice as it can be easily applied daily from P16, when 
mice are ear notched and genotyped. 
Both male and female D252H/+ mice display marginally but significantly worse neuroscores than wild-
type littermates between P16 and P23, indicating a small but detectable neurological deficit in young 
D252H/+ mice (Figure 3g and h;  male D252H/+ vs +/+, p=0.0006; female D252H/+ vs +/+, p= 0.0001) 
which resolves with age (Figure 3i) (possibly due to training). No such neurological deficit is seen in 
heterozygous null animals (Figure S8c and d). 
D252H/+ mice show reduced grip strength  
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As both known human patients with D252H mutations have microcephaly, gross brain morphology of 
60 day old D252H/+ mice was measured by taking coronal slices of PFA-fixed brain at defined locations 
relative to the Bregma, and comparing relative contribution of each layer of the cortex to overall cortical 
thickness. No reductions in head size nor gross brain morphology were found between D252H/+ mice 
and wild-type littermates (supplementary figure S4). Female D252H/+ mice have slightly higher brain 
to body weight ratios than wild type littermates (Figure 4a) due to their brains weighing 96% that of 
wild type littermates’ brains, but bodies weighing 90% that of their wild type littermates’.   Male 
D252H/+ show no change in brain to body weight ratio as their brains and bodies are both 96% of wild 
type at this time point.  
Previous studies have found noted loss of muscle bulk in eEF1A2-null mice (31). The muscle to body 
mass ratio of D252H/+ mice was calculated and the female mice were found to have a significantly 
reduced ratio (p=0.029 two tailed t-test) , whereas male D252H/+ do not (p=0.84 two-tailed t test).  The 
muscle weights of D252H/+ female mice were found to be 79% those of wild type littermates, whilst 
their total body weights were 90% of wild type. 
Mutations in EEF1A2 in humans are associated with hypotonia, or low muscle tone, often associated 
with reduced muscle strength. In order to establish whether the same effect is seen in mice, juvenile 
D252H/+ mice of both sexes were tested for grip strength at P22. Whilst a difference in forelimb-only 
grip strength was only observed in female mice (Figure 4d), both male and female D252H/+ mice were 
found to have impaired all-limb grip strength compared to wild-type littermates (Figure 4c). Mice tested 
at 8 weeks were found to have normal grip strength (Figure 4e-f). This is in contrast with mice 
heterozygous for a deletion mutation in eEF1A2, which have normal motor function as measured by 
grip strength and rotarod (21).  
These findings, along with the impairments in neuroscore and lowered body weight, demonstrate that 
the three week-old D252H/+ mouse has subtle but measurable and clinically relevant phenotypic 
features against which therapies could be tested.  
D252H/+ mice show a mild motor deficit on the accelerating rotarod but no behavioural abnormalities 
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The motor coordination and balance of D252H/+ mice was tested using the accelerating rotarod. Adult 
female D252H/+ mice showed significantly worse performance on the rotarod than wild type littermates 
(2-way repeated measures ANOVA showed significant effect of genotype: F (1,14) = 11.55, p = 0.0043) 
but genotype was not found to have an effect on rotarod ability in male D252H/+ mice.   
As many individuals with mutations in EEF1A2 have been reported to show autistic behaviours, 
D252H/+ mice were put through a battery of tests designed to reveal signs of anxiety or hyperactivity, 
differences in sociability, spatial memory, and repetitive behaviours. Due to the motor deficiency seen 
in female mice when tested on the rotarod, the behavioural test were restricted to male mice. In all 
behavioural tests performed (figure 5) no differences were seen between D252H/+ and wild-type mice. 
Comparison of eEF1A2 missense and null mice to determine whether the D252H mutation results in 
loss- or gain-of-function 
Having compared D252H/+ mice with wild-type littermates to evaluate the D252H mouse as a model 
for EEF1A2 mutations in human, we sought to use the line to provide critical information on the mode 
of action of the mutation itself. We reasoned that comparing mice homozygous for the missense 
mutation (D252H/D252H) with eEF1A2 homozygous null mice (-/-) on the same genetic background 
could yield insights into how the mutation changes the function of the eEF1A2 protein at a physiological 
level. If homozygous missense mice have a more severe phenotype than homozygous knock-out mice, 
this would indicate that the knocked-in mutation confers a toxic gain-of-function. Such experiments can 
now be easily performed using CRISPR-Cas9, since engineering a knock-in model will often involve 
the simultaneous, unintended, production of knock-out founder animals (since non-homologous end 
joining repair generates deletions). We compared mice homozygous for the D252H mutation of Eef1a2 
(D252H/D252H) with Eef1a2 -/- mice. These null mice  carry a 22bp deletion in exon 3 of Eef1a2 
(figure S7a)  resulting in a premature stop codon predicted to result in nonsense-mediated decay, and 
were generated as a by-product of a CRISPR knock-in experiment (22); both experiments were 
conducted using C57BL/6 donors. Mice homozygous for the deletion in exon 3 express a 10-fold 
reduction in eEF1A2 mRNA compared to wild type (figure 6a) and no detectable eEF1A2 protein using 
two different antibodies directed against either terminal of eEF1A2 (Figure 6b and S7b). Importantly, 
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homozygotes on this genetic background show a high number of sudden deaths and spontaneous fatal 
seizures around 22 days. The weight-loss profiles do not therefore extend to the age at which body 
weight is significantly different from wild type littermates, as seen in the original eEF1A2-null mouse 
on a mixed background (31). However, the weight-loss profiles of both the del22.ex3 and wasted mouse 
lines are comparable (figure S7c).  
Comparative phenotyping of D252H/D252H and -/- mice reveals both loss and gain-of-function 
D252H/D252H mice, at first sight, appear similar in phenotype to -/- mice, suggestive of a loss of 
function in the D252H/D252H mice. Weight gain between P14 and P22 is attenuated in both 
D252H/D252H and -/- mice (figure 6c and d), and both lines show neurological deficits in comparison 
to wild-type littermates (Figure 6e and f). We examined pathology in the spinal cord, as null mice have 
no obvious pathology in the brain but show severe neuronal loss in the spinal cord (31). Spinal cords of 
both -/- and D252H/D252H mice show abnormal pathology when sectioned (Figure S6b), including 
loss of normal nuclear structure with apparent loss of nuclear membrane leading to neuronal death in 
anterior horn motor neurons. Sections stained against glial fibrillary acidic protein (GFAP) as a marker 
of gliosis show increased GFAP expression in both D252H/D252H and -/- spinal cords compared to 
wild type (supplementary figure S6a and S6b). This neurodegenerative phenotype is consistent with 
that previously reported in wasted mice, and is consistent with a loss of function in eEF1A2 causing 
cellular lethality.  
The weight gain profile of juvenile mice shows a sex-specific phenotypic difference between missense 
and null mutant mice. Whilst D252H/D252H females have a weight profile similar to that of -/- females, 
male D252H/D252H mice not only weigh less than -/- males at 15 days, they essentially fail to gain 
weight thereafter. There is a significant difference in weight between D252H/D252H and null males at 
every day from 15 days until mice have to be culled at ~22 days (Figure 6c and d).    
Comparison of the D252H/D252H and -/- mice shows that neurological dysfunction in D252H/D252H 
mice, as measured by neuroscoring (note that the mice die before they are old enough to be tested on 
the rotarod) worsens progressively from 16-23 days. Importantly, the scores indicate a significantly 
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more severe neurological phenotype in the D252H/D252H mice than in the -/- mice, in both males and 
females (Figure 6e and f).  
The greater severity of neurological deficit in both sexes and worse weight gain profile in males indicate 
that mice carrying the D252H mutation on both copies of the Eef1a2 gene are more severely affected 
than mice expressing no eEF1A2 at all. The D252H mutation therefore appears to confer a novel toxic 






The unusual mutational profile for EEF1A2 in affected individuals (numerous independent missense 
changes, but no internal deletions or mutations leading to premature termination) suggests that the 
mutations causing severe epilepsy and ID may not operate through a simple loss of function mechanism 
(23). Establishing the functional consequences of mutations in eEF1A2 is not trivial, because unlike 
fully differentiated neurons and muscle in vivo, all cell lines express high levels of the near-identical 
protein eEF1A1, with the potential to mask any gain or loss of function of eEF1A2. We therefore 
exploited the power of CRISPR/Cas9 gene editing to recreate both missense and null alleles in mice, 
and compared the resulting phenotypes. This phenotyping, in conjunction with proteomic analysis, has 
for the first time shed light on the way in which one of the pathogenic mutations in EEF1A2 operates.  
We first showed, using an unbiased proteomic approach followed by confirmatory coIP, that the D252H 
mutation inhibits the binding of eEF1A2 to all components of the GTP exchange factor eEF1B complex. 
This suggested a possible loss of function (see below) but in order to test this, and to generate a mouse 
preclinical model, we used CRISPR/Cas9 editing to recreate the mutation in vivo. This was successful, 
with 16/27 founders having mutations at the correct locus of which two had clean missense mutations 
encoding the D252H mutation. 
We then generated lines of D252H/+ mice, accurately recapitulating the genotype of affected human 
individuals. We analysed expression of eEF1A2 in brain and muscle from heterozygous and 
homozygous mice in order to assess any impact of the mutation on protein stability. Whilst expression 
at the RNA level was unaltered in the mutants, eEF1A2 showed reduced abundance at the protein level 
in the brains of heterozygous (80%) and homozygous mice (60%), suggesting some effect of D252H 
on stability. Surprisingly, this reduction was not seen in muscle, and indeed levels of mutant eEF1A2 
in homozygotes are even higher than in controls. The reasons for this are unclear but it is possible that 
there are differences in post-translational modifications and or higher order complexes in the different 
tissues and that these differentially influence stability of the mutant protein. 
The D252H/+ mice showed no evidence of spontaneous seizures, but this is consistent with the clinical 
picture for this specific mutation (one child with this mutation has not been diagnosed with epilepsy 
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and the other had no seizures before the age of 8). The heterozygous missense mice showed no clear 
behavioural phenotypic abnormalities, including in tests commonly used as surrogates for autistic 
behaviours (though this is not unprecedented in mouse models of NDD (32, 33)). Spatial memory, as 
measured by the Y maze, appeared normal although more sophisticated tests might reveal more subtle 
effects. The heterozygous mice did, however, show consistently reduced body weight and elevated 
neuroscores at 16-22 days postnatal in comparison with their wild-type littermates. They also had a 
significant deficit in all four limb grip strength at 22 days. These phenotypic abnormalities are subtle 
but consistent with neurodevelopmental abnormalities.  
We next tested the hypothesis that the D252H variant is a loss of function mutation by comparing the 
phenotypes of mice with missense and null mutations. Heterozygous D252H/+ animals show subtle but 
significant differences from their wild-type littermates, including lower body weight (unlike +/- 
animals), transiently worse neuroscores and reduced grip strength. The homozygous D252H/D252H 
mice share features of spinal cord neurodegeneration with the homozygous null mice, consistent with 
previous studies of wasted mice that have a spontaneous null mutation in eEF1A2 (31). These results 
are suggestive of a loss of function of eEF1A2 in the presence of the D252H mutation (since the 
expression levels of mutant protein are in excess of those seen in unaffected heterozygous null animals). 
However, the missense homozygous mice are more severely affected in terms of neurological function 
and body weight than their age-matched homozygous null counterparts, in spite of a common genetic 
background. This suggests that the mutation causes toxicity giving rise to an additional gain of function.  
The loss of binding of mutant eEF1A2 to the eEF1B complex might be predicted to result in impairment 
of protein synthesis. However, our attempts to measure protein synthesis in mouse muscle in vivo (to 
avoid the confounding presence of eEF1A1) using SUnSET (34) gave highly variable results, including 
an apparent signal in the homozygous null mice preventing us from drawing direct conclusions.  This 
technique has recently been noted to give variable results in vivo depending on cell type (35). It is hard 
to judge the functional consequences of failure of eEF1A2 to bind eEF1B on whole organism 
physiology, and in fact there is evidence that the effects might not be severe. RNAi knockdown in 
mammalian cells showed that eEF1B subunits are dispensable for function, at least in the short term 
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(36), and recently an Eef1b2 knockout mouse was found to be viable (37). No humans with clear null 
mutations in genes encoding eEF1B subunits have been described, although there are individuals with 
mutations in eEF1B subunits with neurodevelopmental disorders (23).   
In addition to the apparent loss of function of eEF1A2 in the presence of the D252H mutation, the 
homozygous D252H mice showed significantly more severe growth retardation than the null mice, most 
notably across the whole time course in males. Both sexes had significantly worse neuroscores than null 
mice from as early as 16 days. This profile, of a more severe phenotype in missense mice than in nulls, 
strongly suggests a toxic gain of function of the D252H mutation.  
The lower than normal body weight associated with the presence of D252H mutant protein could be a 
reflection of the relationship between protein synthesis and cell size. However, the homozygous null 
animals show no difference in body weight in comparison with normal littermates until ~21 days. In 
terms of the clinical profile of children with missense mutations the picture is inconsistent due to 
reporting differences, but the case with a D252H mutation described by Nakajima et al was reported to 
be 2.5 SD for height and -1.2 SD for weight at age 8. Children with mutations in EEF1A2 have been 
reported to have hypotonia, and the heterozygous missense mice have grip strength abnormalities at 22 
days. These findings in the mice, whilst non-specific, are thus consistent with those in humans. In 
contrast, there were no behavioural abnormalities detected in the heterozygous mice that would model 
those seen in affected children.  
Ultimately, the severity of any given mutation may depend on a balance between any toxic effects and 
the effect of the mutation on protein stability- less stable proteins would presumably be less toxic and 
the resulting phenotype more like a heterozygous null. Phenotypic severity will undoubtedly also 
depend on the location of mutations on the protein, and changes in binding partners. Further animal 
models recapitulating different missense mutations will be needed to address the mechanistic impact of 
each on the function of neurons and muscle.  
Finally, although many questions remain about the functional consequences of mutations in eEF1A2 at 
the molecular level, we have successfully made a line of mice that recapitulate one of the clinically 
relevant mutations seen in humans. The finding that this missense mutation has important implications 
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for the design of therapeutic approaches, since it may be necessary to ablate expression of the mutant 
protein alongside any replacement based treatment. The phenotypic abnormalities we describe have 
sufficient similarities with those seen in children that the new lines will serve as valuable preclinical 





Materials and methods 
Construct generation 
The eEF1A2-V5 construct was created by cloning the eEF1A2 cDNA sequence in to the backbone of 
the pcDNA3.1-V5 vector (Invitrogen). D252H mutation was introduced using the Quik Change II site 
directed mutagenesis kit (Agilent). 
Label-free quantification mass spectrometry 
P12-14 SH-SY5Y Cells were transfected using the Turbofect (Thermo Fisher) protocol. 20µg of DNA 
was transfected into separate T75 flasks. Cell pellets were stored at 80°C, then were resuspended in ice-
cold RIPA buffer (150mM sodium chloride, 1% (v/v) NP-40, 0.5% (w/v) sodium deoxycholate, 0.1% 
(v/v) SDS and 50mM Tris-HCL (pH8) + cOmplete mini protease inhibitor (Roche)), lysed in a 
Bioruptor for 7 cycles of 30 seconds on and off at 4°C, then spun at 13300xg for 20 minutes. The 
supernatant was removed and taken for immunoprecipitation.  
To isolate eEF1A2-V5 and binding partners, samples were incubated at 4°C for 3 hours with V5 agarose 
magnetic beads (MBL international), using the KingFisher Duo II robot system. After incubation, the 
the beads were washed 3 times with 500µl of RIPA buffer and a further 2 times in 500µl TBS. Finally, 
beads were deposited in trypsin working reagent (42.9mM trypsin protease (Pierce, MS grade), 1mM 
DTT, 2M UREA, 50mM Tris pH8). Samples were left overnight to digest at 4°C and peptide fragments 
were collected.  Samples were then maintained at -20°C until loading onto the Thermo-Q Orbitrap mass 
spectrometer for label free quantification (LFQ). LFQ intensities were normalised using two 
complementary methods: bait normalisation and most-likely ratio normalisation (MLR)  (24). Fold-
change from the wild-type condition were calculated using both these normalisation strategies.  
Co-Immunoprecipitation 
2.8x106 SHSY5Y cells in a T25 flask were transfected with the eEF1A2-V5 construct using Turbofect 
(Thermo Fisher). After 48 hours cells were trypsinised, spun and pellets lysed in 100ul RIPA buffer. 
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Cells were sonicated using the Bioruptor (Diagenode) for 7 cycles of 30 seconds on and off. Lysates 
were spun at 10,000g for 15 minutes and supernatant collected. A bead solution was made by diluting 
V5 agarose magnetic beads (MBL International) 1 in 10 in RIPA buffer. 10µl of bead solution were 
added to the cells lysates and samples incubated for 3 hours at 4°C with rotation. Samples were spun in 
a centrifuge for 2 minutes at 8000 rpm. Using a magnetic Eppendorf rack (Active Motif), beads were 
isolated and lysate extracted. These lysates were diluted 1:1 in 2X Laemmli buffer and 10% 1M DTT, 
boiled for 10 minutes at 95°C and stored at -20°C as the ‘input’ fraction. Beads were washed in 100ul 
RIPA buffer 3 times and with 300ul TBS twice using volumes described above. 2X Laemmli buffer 
and RIPA buffer were mixed 1:1 and added to beads. Tubes were incubated for 10 minutes at 95°C, 
then re-applied to the magnetic rack and supernatant collected. The sample was supplemented with 10% 
v/v 1M DTT and stored at -20°C as the IP fraction.  For western blotting, 15µl of IP fraction and 5µl of 
input fraction were used with the following antibodies: eEF1Bγ anti-rabbit 1:1000 (Abcam), eEF1Bα 
anti-rabbit 1:250 (Proteintech), eEF1Bδ anti-rabbit 1:1000 (Proteintech), ValRS anti-rabbit 1:250 (St 
Johns laboratory) , and V5 anti-mouse 1:1000 (Invitrogen). Secondary antibodies were light chain 
mouse anti-rabbit HRP 1:1000 (Abcam) and light chain donkey anti-mouse HRP 1:1000 (DAKO). All 
incubations were 1 hour room temperature unless otherwise specified.  
 
CRISPR/Cas9n gene editing 
Guide RNA pairs were designed from target sequence of mouse Eef1a2 around exon 5 using online 
tools at http://crispr.mit.edu/. They were synthesised, annealed and cloned into vector px458 from 
which they were in vitro transcribed. The sequences were amplified using universal reverse primer and 
T7-tagged forward primers. The guide RNA PCR template was used for in vitro RNA synthesis using 
T7 RNA polymerase, and the RNA template was subsequently purified using RNeasy mini kit (Qiagen) 
purification columns. Cas9 nickase mRNA was procured from Tebu Bioscience. The repair template 
was designed and synthesised as 200bp PAGE-purified ssODN Ultramer by IDT. 
Transgenic mouse generation 
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Mice were housed in the Biomedical Research Facility (BRF) at the University of Edinburgh. All mice 
were maintained in accordance with Home Office regulations and all protocols had been approved by 
the local ethics committee of the University of Edinburgh. All methods were performed in accordance 
with the relevant guidelines and regulations. Embryo transfer was carried out with short term recovery 
anaesthesia, and analgesia where needed post-operatively. Mutant mice were closely observed for 
overall clinical condition and were euthanized where necessary to avoid suffering.  
Transgenic mice were made using pronuclear injection of CRISPR reagents into oocytes derived from 
C57BL/6JCrl mice. The microinjection mix was prepared with components at the following 
concentrations: gRNAs 25 ng/ul each, Cas9n mRNA at 50 ng/ul and Ultramer ssODN repair template 
150 ng/ul. There were 28 live born mice as a result of this procedure; two of which were found to carry 
the desired point mutation in Eef1a2 (c.G754C) and became founders of the transgenic mouse lines 
used in subsequent experiments described here.  
Mice that survived weaning were housed in single sex, mixed genotype groups of between 2 and 5 
animals.  Both male and female mice were characterised, numbers and ages of mice are described for 
each test. All phenotyping was carried out blind to genotype. 
Genotyping  
Ear notches were taken at 14 days after birth, DNA extracted and used for PCR genotyping, initially by 
direct sequencing when identifying founders, then after establishment of D252H colonies by restriction 
digests of PCR products to detect the presence/absence of the Hin1II restriction site created by the 
D252H mutation. PCR primers used were 5’-3’ AGGCTACCCCTTAGGCAGGT, 
TGAACAAATGGTAGGTGGGAGG.  Animals from the eEF1A2-/- line were genotyped by PCR of 
the region flanking the 11bp deletion using primers 5’-3’ TGAGTTGTGCCTCTACCCTT, 
ACACCTGGGATGTGCCTGTA, The product of the deletion allele was  186 bp and the WT equivalent 





Whole brains and hind limb muscles were dissected, frozen on dry ice and stored at -70°C until use. 
They were homogenised in 10µl/mg tissue 0.32M sucrose containing protease inhibitor (cOmplete 
Mini, Roche) then centrifuged at 17,000g at 4°C for 30 minutes. The supernatant was removed and 
mixed with 4x NuPAGE LDS sample buffer and 10x NuPAGE reducing agent, then heated to 70°C for 
10 minutes. Lysates were loaded onto NuPAGE 4-12% bis-tris gels and run at 200V in NuPAGE MOPS 
SDS, before being transferred onto PVDF membrane (Amersham Hybond) in NuPAGE transfer buffer. 
Total protein on the blots was visualised using Revert solution (LI-COR). Blots were then blocked in 
Odyssey blocking buffer (LI-COR) for 1 hour, incubated either 1:5000 in an antibody to eEF1A2 
(custom made by Proteintech) or 1:2000 in rabbit anti-eEF1A2 (ab82912 Abcam) for 1 hour, washed 
in TBS buffer containing 0.01% tween-20 for 3x 15 minutes, then incubated in IRdye 800CW anti-
rabbit (LI-COR) secondary antibody for 1 hour.  After another set of washes, images were taken using 
the Odyssey CLx (LI-COR) and analysed on Image Studio Lite Version 5.2. eEF1A2 levels were 
measured by normalising each eEF1A2 band to total protein levels within the lane. All Western blots 
were performed in triplicate. Differences in the eEF1A2 expression of D252H/+ and D252H/D252H 
mouse tissues were expressed as fold-change difference from the mean wild type signal.  
RNA analysis 
RNA from brain was extracted using the QIAGEN RNeasy mini kit and DNase digested using the 
QIAGEN RNase-Free DNase Set. cDNA was then synthesized using the Agilent Technologies 
AffinityScript Multi Temperature cDNA Synthesis Kit. Quantitative RT-PCR (qPCR) was performed 
on the cDNA using primers for eEF1A2 exon 2-4 (5′ GCCACGATCAGCACTGCG and 5′ 
CAAGCGGACCATCGAGAAGT), eEF1A2 exon 3-4 (5’ATATGATTACAGGCACATCCCAG and 
5’GTGCGTGTTCCCGGGTTT), Actin (5’ TCCATCATGAAGTGTGACGT and 5’ 
GAGCAATGATCTTGATCTTCA) and GAPDH (5’GGAAGGGCTCATGACCACA and 
5’CCGTTCAGCTCTGGGATGAC) were selected as suitable reference genes after analysis with a 
geNorm 6 gene mouse kit (PrimerDesign). Brilliant II SYBR Green QPCR master mix (Agilent) was 
used to make the reaction mix. cDNA was diluted 1:10 and 4µl added to each reaction. Sample were 
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run in triplicate in a LightCycler HT7900 (Roche) and quantity means were calculated using Ct values 
along with the slope and the Y-intercept from the standard curve for each gene.  
Grip strength  
Limb muscle strength was measured at P22 and 8 weeks of age using a grip strength meter (Bioseb). 
Grip strength from all four limbs or front limbs only was measured in triplicate with a 1-minute break 
in between each test to allow the mouse to rest. For each test the mouse was held by the base of the tail 
and lowered onto the grid until it gripped with either the front paws or all four paws, and then pulled 
horizontally away from the grid. The maximum force (Newton, N) was recorded.  
Neuroscore 
To assess the neurological phenotype of mutant mice four tests adapted from Guyenet et al, (25) were 
applied to each animal from P16 to P22, and at 8 weeks of age: Ledge walking, hindlimb clasping, 
observation of gait, degree of kyphosis. The response of the mice to each test was scored between 0 and 
3, and the four test scores combined to give an overall ‘neuroscore’ between 0 and 12, where a higher 
number indicates a more severe neurological phenotype. The protocol and scoring criteria for each test 
are found in supplementary methods 1.  
Rotarod 
Mice were tested for balance or motor deficiencies by measuring how long they could stay on an 
accelerating rotating beam (Bioseb). Mice were trained on day 1 of the experiment by placing them on 
a rotarod moving at a constant speed of 4rpm. Mice were replaced back on the rotarod if they fell off 
until they were able to stay on for at least a minute without dropping. At this point the rotarod was 
accelerated from 4 to 40rpm over 2 minutes. When mice fell off in this phase they were not replaced on 
the beam. Mice were rested for 30 minutes and then tested as follows: mice were placed, facing away 
from the investigator, on a beam rotating at 4rpm. The rotarod was then accelerated to 40rpm over a 
period of 2 minutes and the time taken for mouse to drop recorded, up to a maximum time of 3 minutes. 
Mice were tested three times per day with a 30 minute rest period in between. Each animal was tested 




For each sex, five +/+ mice and five D252H/+ mice were euthanised at P60. Brains were dissected and 
post-fixed in 4% PFA for 24 hours before being mounted in paraffin. 10 µM coronal sections were 
taken and stained using H&E before being imaged at 20x magnification using a Nanozoomer slide 
scanner (Hamamatsu). Using the Allen mouse brain atlas, brain sections corresponding to Bregma ± 0 
mm and Bregma -1.6 mm were selected for analysis. Annotation and measurement of different brain 
regions was performed using the Ndp.view2 software (Hamamatsu). Brain measurements were 
statistically analysed using repeated measures one-way ANOVA, with each D252H/+ mouse matched 
with one same-sex +/+ littermate.  
Mouse behavioural testing 
Male mice were tested between 2 and 4 months of age, in the order described below. Light levels in all 
tests involving arenas were set to 100 lux. The standard cage described here is 332x150x130mm in size.  
Where appropriate, cages were cleaned between trials with 1% conficlean.  
Marble burying: 20 marbles were placed in 4 rows of 5 in a standard cage containing 5cm of fresh 
bedding. The mouse was placed in the cage and allowed to explore for 30 minutes. Videos were 
recorded to score number of marbles 2/3 buried or more. 
Digging: Fresh bedding was added to a standard cage and the test mouse allowed to explore for 3 
minutes. Latency to onset of digging, number of digging bouts and duration of digging bouts were 
measured by the observer..  
Open field: Mice were placed in the centre of a 50x50cm white perspex arena with 38cm high walls, 
allowed to explore for 5 minutes and recorded from above.  Videos were analysed using Any Maze 
software to determine total distance travelled by the mouse, time spent freezing and time spent in the 
central area (this was defined as a 30cm x30cm area in the centre of the arena).   
Y-maze: The Y-maze was made of clear perspex with three 40x10cm arms set at 120° to one another, 
with 16cm-high walls.  The floor of the maze was covered with fresh bedding and a handful of bedding 
from each cage of the test mice. The test mouse was placed in one arm of the maze facing the end wall 
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and allowed to explore two arms for 5 minutes. After a 15-minute inter-trial interval (ITI), the gate 
closing the third arm was removed and mouse placed back in the same start arm and allowed to explore 
the maze for 2 minutes. Bedding was mixed and gate and maze walls cleaned with 1% conficlean 
between trials. Videos were scored for time spent in each arm during test phase.  
Stranger mouse exposure: The stranger mouse experiment was carried out in the Y-maze arena. The 
start arm was closed using a gate and two wire mesh gates were placed in each arm to form 10cm-long 
enclosures halfway along the second and third arms. The test mouse was habituated to the y-maze for 
10 minutes. It was then removed and a novel adult male mouse unrelated to the test mouse placed in 
one of the 10cm-long enclosures. The test mouse was returned to the start arm of the maze and allowed 
to explore for 10 minutes. The test mouse was then removed again and a second novel mouse placed in 
the other enclosure  in the previously unoccupied arm. The test mouse was then returned to the start 
arm and allowed to explore for another 10 minutes. The positions of novel mouse 1 was counterbalanced 
between mice. Exploration was defined as the test mouse being in close proximity to and facing the 
stranger mouse/gate.  
Nest Building: Fresh mouse bedding was added to a clean cage and a 5cm x 5cm square of nest material 
weighed and placed in the centre. The test mouse was placed in one corner of the cage and then left 
overnight. The nestlet was then removed from the cage, allowed to dry overnight and scored according 
to the scale devised by Deacon(26). 
Pathology 
P22 mice were euthanised and spinal columns were dissected and fixed in formalin for 24 hours  then 
decalcified for 3 weeks in 10% EDTA (pH7.4; changed weekly), and then placed in formalin for 24 
hours. Sections were stained with haematoxylin and eosin by Division of Pathology, University of 
Edinburgh. Other sections were immunostained for GFAP by taking sections to water, treating with 
proteinase K for 10 minutes, washing in water, treating with 3% hydrogen peroxide for 10 minutes and 
then rewashing in water followed by PBS. Sections were blocked for 10 minutes in goat serum, 1:5 in 
PBS, then incubated in 1:500 GFAP anti-rabbit antibody (Z0334 Dako) overnight, biotinylated 
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secondary goat anti-rabbit 1:500 for 30 minutes, Streptavidin ABS for 30 minutes and DAB for 2 
minutes, with 5 minute PBS washes between each step. Slides were counterstained with haematoxylin.  
Protein modelling 
A BLAST alignment (27) confirmed the human eEF1A2 sequence [residues 1-463; NCBI reference 
sequence: NP_001949.1] had a sequence identity of 100% (E value of 0.0) against the Oryctolagus 
cuniculus eEF1A2 structure available in the Protein Data Bank. The human eEF1A2 protein structure 
was then modelled through the program I-TASSER (Iterative Threading Assembly Refinement) (28) 
which utilises meta-threading, replica-exchange Monte Carlo simulations and identification of the 
lowest free energy states via SPICKER. The resulting .pdb file was then loaded into PyMOL (The 
PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC) and the mutagenesis tool 
employed to create the D252H mutation, with a rotamer of the lowest free energy and atomic overlap. 
Statistics All statistics were performed using GraphPad Prism V8 or in R. T-tests were used in cases 
where two datasets were compared, except where data were not normally distributed, in which case the 
Mann-Whitney test was used. Time courses were analysed with repeated measures ANOVA (Figures 
3a and 3d, 4g, 4h) or linear mixed models in the cases where some measurements were missing (Figures 
3b, 3e, 6b and 6c). LMMs included fixed effects of genotype and age, with animal ID as a random 
effect, fits were performed using the “lme4” R package (29), and post-hoc tests were performed using 
the “lsmeans” R package (30). Neuroscore time-courses (a non-continuous measure) were analysed 
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Figure 1 The location of the D252H mutation in human eEF1A2 and effect on binding partners 
(a) Location of missense mutation D252H and known binding sites mapped onto 3-D model of yeast 
eEF1A using PyMOL. The equivalent locations of the eEF1Bα (yellow) and the GTP/GDP (blue) 
binding sites are also highlighted as in (1). (b) Changes in the eEF1A2-interactome due to the D252H 
mutation after affinity-purified mass-spectrometry of cell lysates transfected with either wild type or 
mutated (D252H) eEF1A2-V5.  Volcano plot shows Log2 fold change plotted against the corresponding 
-log10 p-value. P-values were calculated using one t-test per protein with a 1% FDR correction for 
multiple testing. Proteins were defined as significant (green) when there was a log2 fold change greater 
than 1 and p < 0.05. Non-significant proteins were identified in blue. (c) Co-immunoprecipitation 
experiments in SH-SY5Y cells carried out in duplicate transfections.  eEF1A2-V5 was isolated using 






Figure 2 A mouse line carrying the D252H mutation was engineered using CRISPR. (a) The gRNA 
sequences used are blue, bases mutated in the repair template to alter the PAM sites are highlighted 
green. The site of the desired mutation 754G>C (D252H) is highlighted yellow. (b) Mice born after 
microinjection of CRISPR components according to  genotype. (c) Sequencing chromatogram of DNA 
isolated from one of the two founders. The two overlaid peaks at the position marked ‘S’ show the 
sequenced mouse to be heterozygous for the 754G>C mutation (d) qPCR analysis of RNA taken from 
the brains of 3 D252H/+ and 3 D252H/D252H mice using primers within eEF1A2 shows no significant 
difference between genotypes (1-way ANOVA F(2,6, ) = 0.32 P= 0.7) (e) Representative western blot 
of muscle lysates from wild type and D252H mutant P22 mice showing eEF1A2 abundance normalised 
to total protein levels, quantified in (f) p=0.0006 t(16)=4.2 unpaired two-tailed t test. (g) Representative 
western blot of brain lysates from wild type and D252H mutant mice, quantified in (h) p=0.0002 
t(18)=4.5 unpaired two-tailed t test. Each dot in (f) and (h) represents single mouse and is the mean of 







Figure 3 Body weights and neuroscores of D252H/+ mice and wild type littermates. (a) male and 
(d) female D252H/+ and wild type littermate mouse weights between 3 and 13 days post birth, n=12. 
Repeated measures ANOVA shows no significant difference between genotypes. (b) Male and (e) 
female body weights between 14 and 22 days post birth n>12  (male D252H/+ vs +/+, p=0.0001; female 
D252H/+ vs +/+, p= 0.0018; linear mixed model)  (c) male and (f) female  body weights of adult 
D252H/+ and +/+ littermates at 8 weeks post birth. Male (p=0.009 t(17)=2.9) and female (p=0.001 
t(21)=4.3) D252H/+ mice weigh significantly less than +/+ littermates, two-tailed unpaired t test. (g) 
Male and (h) female neuroscore between 16 and 23 days post birth (male D252H/+ vs +/+, t(38.3)=3.75, 
p=0.0006; female D252H/+ vs +/+, t(62.0)=4.08, p= 0.0001; unpaired two-tailed t-test, animal means).  
(i) Male and female adult neuroscores show no significant difference between D252H/+ and wild type 






Figure 4: Body measurements, grip strength and rotarod performance of D252H/+ mice. (a) Brain 
and (b) muscle weights of P22 D252H/+ and wild type littermates expressed as ratio to body weight. 
Welch’s t-test shows female D252H/+ have a higher brain to body weight ratio than wild type 
littermates (p=0.009 T(16)=2.9)) and a lower muscle to body weight ratio (p=0.002 T(13)-3.7). (c) All-
limb and (d) front-limb grip strengths of P22 D252H/+ mice and wild type littermates. Two-tailed  
unpaired t tests show males and females have impaired all-limb grip strength at P22 (males p<0.0001 
t(26)=4.6, females p=0.0002 t(228)=4.3) and females also show an impaired front-limb grip strength 
(p=0.0056 t(28)=3.0). (e) all-limb and (f) front-limb grip strengths at 8 weeks of age show no significant 
difference from wild type using an unpaired t-test.  (g) Female and (h) male rotarod experiments (n=8 
for each sex/genotype)  show female D252H/+ have an impaired ability on the rotarod compared to 
wild type littermates (2-way repeated measures ANOVA showed significant effect of genotype for 








Figure 5 Behavioural phenotyping of adult D252H/+ mice.  (a) repetitive behaviour measured by 
marble burying test shows no significant difference in number of marbles buried between D252H/+ and 
+/+ littermates. (unpaired t-test). See also supplementary figures S5a-e for other repetitive behaviour 
tests. (b) open field test measuring anxiety and hyperactivity. No significant difference is seen between 
genotypes in the time mice spend in the centre of the maze (unpaired t-test). See also supplementary 
figures S5f-g.  (c)  Y-maze test measuring spatial memory.  D252H/+  mice show normal preference 
for social novelty as defined here by a novel:familiar ratio not equal to zero (One sample-Wilcoxon test 
+/+  p= 0.002 W=55, D252H/+ p=0.002 W=55 ), but there is no significant difference in novel:familiar 
ratio between genotypes (Mann-Whitney two-tailed  test p=0.19 U=32) (d) Stranger mouse test show 
D252H/+  mice have normal sociability, preferentially exploring a y-maze arm containing a stranger 
mouse over an empty arm of the y-maze. (One sample-Wilcoxon test +/+  p= 0.001 W=66, D252H/+ 
p=0.002 W=55)  with no significant difference  between genotypes (Mann-Whitney two-tailed test 





Figure 6 Comparison of homozygous D252H/D252H mice with the eEF1A2 knockout (-/-) mouse 
(a) qPCR showing the mRNA levels of eEF1A2 in -/- brain, measured using two primer sets which 
amplify a region 3’ of the deletion site (exon 3-4) and a region spanning the deletion site (exon2-4) 
respectively. (b) Western blot showing that the eEF1A2 knockout mouse does not express eEF1A2 
protein in brain.  (c)  Male and (d) female body weights of D252H/D252H, -/- and wild type littermate 
mice between 14 and 22 days of age (male D252H/D252H vs +/+, p < 0.0001; male -/- vs +/+, p=0.267; 
male D252H/D252H vs -/-, p = 0.0005; female D252H/D252H vs +/+, p < 0.0001; female -/- vs +/+, 
p=0.011; female D252H/D252H vs -/-, p=0.5188; linear mixed models)  (e) Male and (f) female 
neuroscores of D252H/D252H, -/- and wild type littermate mice between 16 and 23 days of age  (male 
D252H/D252H vs +/+, p < 0.0001; male -/- vs +/+, p < 0.0001; male D252H/D252H vs -/-, p < 0.0001; 
female D252H/D252H vs +/+, p < 0.0001; female -/- vs +/+, p < 0.0001; female D252H/D252H vs -/-, 






Supplementary Figure S1  Changes in the eEF1A2-interactome due to the D252H mutation after 
affinity-purified mass-spectrometry of cell lysates transfected with either wildtype or mutated (D252H) 
eEF1A2-V5.  List of proteins with greater than 0.5 log2 fold change between wildtype and mutant 
conditions, listing both bait-normalised and MLR-normalised data for each gene. Genes listed in order 
of largest fold-change to smallest.  
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 Supplementary Figure S2 (a) Sequences of the two repair templates used to engineer the D252H 
mutant mouse. Sequences corresponding to exonic regions of genomic DNA are capitalised. Areas that 
correspond to the gRNA sequences are in light blue, with PAM sites in dark blue. The amino acid 
change used to encode the D252H mutation is in red.  (b) Weights and (c) Neuroscores of mice taken 
from the two D252H lines referred to as D252H.15 and D252H.16, at P21.  t-tests showed no significant 
difference between lines in either weight (males p=0.77 t(9)=0.3 females p= 0.54 t(9)=-0.6) or 






Supplementary Figure S3 Western blots of muscle lysates from wild type and D252H mutant mice 
and qPCR melt curves and standard curves.  (a) muscle and (b) brain lysates showing eEF1A2 
expression normalised to total protein levels. Each point on graph is data from a single mouse, over 
three technical replicates. eEF1A2 levels in male and female mice are not significantly different in 
either muscle (a) or brain (b) lysates (unpaired t-tests). (c) qPCR standard curves for eEF1A2 and 
reference genes GAPDH and Actin. Primer sets with R2>0.98 were considered acceptable for further 
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Supplementary Figure S4 Measurements of brain regions in D252H/+ mice. (a) example image of 
an H&E-stained brain section with hippocampus, dentate gyrus granule layer (DGgl) and the layers of 
the primary somatosensory area barrel field (SSp) annotated. At Bregma ± 0, the thickness of each 
cortical layer was measured in the primary motor area (MOp) and the primary somatosensory area barrel 
field (SSp). At Bregma -1.6 mm, the thickness of each cortical layer was measured in the primary 
somatosensory area barrel field (SSp), and the areas of the hippocampus and dentate gyrus granule layer 
(DGgl) were measured. Within each cortical area analysed, three separate measurements of each layer 
were taken per image and averaged. To control for tissue preparation artefacts, cortical layer thicknesses 
were then normalised to total cortical thickness, while hippocampus and DGgl areas were normalised 
to total hemisphere area. (b) male and (c) female MOp and SSp laminar compositions at three positions 
relative to Bregma. There is no significant difference in laminar composition between genotypes at any 
position (repeated measures one-way ANOVA). (d) Hippocampal area and (e) dentate gyrus granular 
layer (DGgl) area in male and female D252H/+ mice and wildtype littermates. There is no signficiant 
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Supplementary Figure S5 Further behavioural tests on D252H/+ mice showed no significant 
differences from wild type littermates (a), (b) and (c) show results from the digging test in which 
mice were placed in a new cage containing 5cm bedding and observed for 3 minutes. (d) (e) show 
results from the nest building test in which mice were placed in a cage with a square of nestlet material 
and left overnight. The percentage of nestlet shredded (d) and the nest score (e) showed no significant 
difference between genotypes. (f) and (g) show further results from the open field test described in 
figure 5b. No significant difference is seen in the total distance travelled by each mouse (f) nor in the 
amount of time spent freezing (g). (h) Stranger mouse test stage 2. D252H/+ mice showed normal 
preference for social novelty as measure by time spent exploring a familiar mouse vs novel mouse. 
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Supplementary Figure S6 Cervical and sacral spinal cord sections of P22 mice (a) stained against 
glial fibrillary acidic protein (GFAP) with strong staining indicated by arrows, (b) H&E-stained with 
vacuolated motor neurons indicated by arrows.  White bar indicates 150um. Genotype of the mouse 











Supplementary Figure S7 Eef1a2-/- mouse sequence alignments and protein expression. (a) DNA 
alignment shows the 22bp deletion at the start of exon 3. The  alignment of +/+ and -/- eEF1A2 protein 
sequences shows the premature stop codon introduced by the deletion, predicted to result in nonsense-
mediated decay.  (b) Western blot showing no expression of eEF1A2 in tissues taken from -/- mice 
using a primary antibody raised against amino acids 1-245 of eEF1A2. (c) a comparison of body weights 








Supplementary Figure S8 Body mass and neuroscores of heterozygous null mice. (a) Male and (b) 
female body masses of heterozygous null (+/-) mice and wild type littermates between 3 and 22 days 
post birth. There is no significant difference between genotypes of either sex (repeated measures 
ANOVA). (c) male and (d) female neuroscores between 16 and 23 days post birth show no significant 










DEE   developmental and epileptic encephalopathies 
AEDs   anti-epileptic drugs 
LFQ-MS label-free quantification mass spectrometry 
ssODN  single-stranded oligonucleotide 
LFQ  label free quantification 
MLR  most-likely ratio normalisation  
qPCR  quantitative RT-PCR  
 
